|
業務類別
|
Biotechnology |
|
業務概覽
|
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities. |
| 公司地址
| 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118 |
| 電話號碼
| +1 408 708-9808 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.anixa.com |
| 員工數量
| 4 |
| Dr. Amit Kumar,PhD |
Chairman of the Board and Chief Executive Officer |
美元 815.17K |
28/01/2026 |
| Mr. Michael J. Catelani |
President, Secretary, Chief Operating Officer, Chief Financial Officer and Principal Accounting Officer |
美元 553.16K |
28/01/2026 |
|
|
| Dr. Amit Kumar,PhD |
Chairman of the Board and Chief Executive Officer |
28/01/2026 |
| Mr. Lewis H. Titterton, Jr |
Lead Independent Director |
28/01/2026 |
| Dr. Arnold Baskies, M.D. |
Independent Director |
28/01/2026 |
| Ms. Emily Gottschalk |
Independent Director |
28/01/2026 |
|
|
|
|
